Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70 participants
OBSERVATIONAL
2010-06-30
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators want to see if PET/CT is able to detect any signs of sub-clinically metastases. Besides, the investigators want to fusion PET/CT with SPECT/CT data from the lymphoscintigraphy study and improve our PET/CT scanning with a dual-time PET scan of the head-and-neck region.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer
NCT01636674
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
NCT01077869
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622
Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study
NCT00686465
Dual PET/CT Imaging in Lung Cancer
NCT01539928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
By combining biomarkers and molecular imaging in patients with a clinically T1/T2N0M0 oral cancer, we want to characterize the tumor physiologically and correlate these physiological features to the clinical appearance of the cancer.
Aims of the study:
* can PET/CT in this patient group metastases with consequently change of treatment?
* can fusion of SPECT/CT and PET/CT with calculation of standardized uptake value (SUV) indicate, how much tumor tissue there should be in a positive sentinel node to be detected by PET?
* can dual-time PET scanning better determine lymph node metastases, than single-time PET scanning?
* correlation between SUV in PET with molecular-biological findings both in the primary tumor and in metastases
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* over 18 years of age
Exclusion Criteria
* inable patients
* pregnancy
* known allergy to contrast agents
* kidney insufficiency
* other known cancer
* diabetes mellitus
* acute medical conditions such as acute infection, acute cardial or lung disease or other intercurrent diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dep. of Nuclear Medicine & PET, Rigshospitalet
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine W Dümcke, Dr.
Role: PRINCIPAL_INVESTIGATOR
Dep. of Nuclear Medicine & PET
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dep. of Nuclear Medicine & PET
Copenhagen, , Denmark
Dep. of otorhinolaryngology, Head & Neck Surgery/ Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RH-238_10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.